New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
07:26 EDTMRK, BDX, ABBV, WPI, OCR, SIAL, REGNGoldman to host a conference
Healthcare CEOs Unscripted Conference is being held in New York on January 3.
News For REGN;WPI;BDX;SIAL;ABBV;MRK;OCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
10:00 EDTBDXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:37 EDTBDXBecton Dickinson reinstated with an Equal Weight at Barclays
Subscribe for More Information
June 30, 2015
07:32 EDTABBVJuno pact leaves Celgene set for growth past Revlimid, says Deutsche Bank
Subscribe for More Information
June 29, 2015
10:09 EDTBDXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:39 EDTMRKMerck says Phase 3 Emend data shows it provides 'greater protection' from nausea
Merck announced results from a Phase 3 study investigating the safety and efficacy of single-dose Emend for Injection, Merck’s substance P/neurokinin receptor antagonist, in combination with other anti-vomiting medicines, for the prevention of chemotherapy-induced nausea and vomiting, or CINV, in adult cancer patients receiving moderately emetogenic chemotherapy, or MEC. In the study, the first to evaluate an intravenous NK-1 receptor antagonist for the prevention of CINV associated with MEC, the single-dose Emend for Injection regimen provided greater protection from nausea and vomiting following administration of chemotherapy versus an active control of placebo with other anti-vomiting medicines. These data were presented in an oral session at the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting on “Supportive Care in Cancer” in Copenhagen.
06:52 EDTBDXBecton Dickinson upgraded to Buy from Neutral at UBS
Subscribe for More Information
June 28, 2015
14:42 EDTSIALMerck KGaA CEO sees U.S. as 'most important' market, WSJ says
Subscribe for More Information
12:22 EDTBDXBD Medical says reusable sharps containers lead to higher rates of C. diff
Subscribe for More Information
June 26, 2015
12:02 EDTABBVEMA adopts positive opinion on AbbVie's Humira for acne inversa
Subscribe for More Information
05:25 EDTREGNRegeneron reports approval of Eylea by Japan
Subscribe for More Information
June 24, 2015
09:07 EDTMRKCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
06:12 EDTABBVAbbVie announces new TURQUOISE-III study results
Subscribe for More Information
June 23, 2015
10:40 EDTOCRCVS Health sees Omnicare transaction closing by end of year
Subscribe for More Information
June 21, 2015
13:14 EDTMRKMerck shares could return 25%, Barron's says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use